London Edra, Rothenbuhler Anya, Lodish Maya, Gourgari Evgenia, Keil Meg, Lyssikatos Charalampos, de la Luz Sierra Maria, Patronas Nicolas, Nesterova Maria, Stratakis Constantine A
Section on Endocrinology and Genetics (E.L., A.R., M.L., E.G., M.K., C.L., M.d.l.L.S., M.N., C.A.S.), Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Inter-Institute Pediatric Endocrinology Training Program (E.G.), and Department of Diagnostic Radiology (N.P., C.A.S.), Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892; and Service d'Endocrinologie Pédiatrique (A.R.), Université Paris-Sud 11, Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France.
J Clin Endocrinol Metab. 2014 Feb;99(2):E303-10. doi: 10.1210/jc.2013-1956. Epub 2013 Nov 18.
The cAMP signaling pathway is implicated in bilateral adrenocortical hyperplasias. Bilateral adrenocortical hyperplasia is often associated with ACTH-independent Cushing syndrome (CS) and may be caused by mutations in genes such as PRKAR1A, which is responsible for primary pigmented nodular adrenocortical disease (PPNAD). PRKAR1A regulates cAMP-dependent protein kinase (PKA), an essential enzyme in the regulation of adiposity. Although CS is invariably associated with obesity, its different forms, including those associated with PKA defects, have not been compared.
The purpose of this study was to characterize the phenotypic and molecular differences in periadrenal adipose tissue (PAT) between patients with CS with and without PRKAR1A mutations.
Samples from adrenalectomies of 51 patients were studied: patients with CS with (n = 13) and without (n = 32) PRKAR1A mutations and a comparison group with aldosterone-producing adenomas (APAs) (n = 6). In addition, clinical data from a larger group of patients with Cushing disease (n = 89) and hyperaldosteronism (n = 26) were used for comparison.
Body mass index (BMI), abdominal computed tomography scans, and cortisol data were collected preoperatively. PAT was assayed for PKA activity, cAMP levels, and PKA subunit expression.
BMI was lower in adult patients with CS with PRKAR1A mutations. cAMP and active PKA levels in PAT were elevated in patients with CS with PRKAR1A mutations.
Increased PKA signaling in PAT was associated with lower BMI in CS. Differences in fat distribution may contribute to phenotypic differences between patients with CS with and without PRKAR1A mutations. The observed differences are in agreement with the known roles of cAMP signaling in regulating adiposity, but this is the first time that germline defects of PKA are linked to variable obesity phenotypes in humans.
环磷酸腺苷(cAMP)信号通路与双侧肾上腺皮质增生有关。双侧肾上腺皮质增生常与促肾上腺皮质激素(ACTH)非依赖性库欣综合征(CS)相关,可能由PRKAR1A等基因突变引起,PRKAR1A负责原发性色素性结节性肾上腺皮质疾病(PPNAD)。PRKAR1A调节cAMP依赖性蛋白激酶(PKA),这是调节肥胖的一种关键酶。虽然CS总是与肥胖相关,但其不同形式,包括与PKA缺陷相关的形式,尚未进行比较。
本研究的目的是描述有和没有PRKAR1A突变的CS患者肾上腺周围脂肪组织(PAT)的表型和分子差异。
对51例患者肾上腺切除术的样本进行了研究:有PRKAR1A突变的CS患者(n = 13)和无PRKAR1A突变的CS患者(n = 32),以及一个产生醛固酮腺瘤(APA)的对照组(n = 6)。此外,还使用了来自更大一组库欣病患者(n = 89)和醛固酮增多症患者(n = 26)的临床数据进行比较。
术前收集体重指数(BMI)、腹部计算机断层扫描和皮质醇数据。对PAT进行PKA活性、cAMP水平和PKA亚基表达检测。
有PRKAR1A突变的成年CS患者BMI较低。有PRKAR1A突变的CS患者PAT中的cAMP和活性PKA水平升高。
PAT中PKA信号增加与CS患者较低的BMI相关。脂肪分布的差异可能导致有和没有PRKAR1A突变的CS患者之间的表型差异。观察到的差异与cAMP信号在调节肥胖中的已知作用一致,但这是首次将PKA的种系缺陷与人类可变的肥胖表型联系起来。